PLGLB2

Across TCGA pan-cancer cohorts, PLGLB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLGLB2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLGLB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLGLB2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

UCEC, HNSC, and PDAC are the cancer types where PLGLB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.376	0.880	.006	16	view →
HNSC	DFS	Tertile	II,III,IV	0.985	0.868	.015	9	view →
PDAC	OS	Median	IV	0.934	0.395	.024	5	view →
LUAD	DFS	Tertile	III,IV	0.486	0.900	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLGLB2–UCEC (DFS)

Open the UCEC breakdown →